Ahammune Biosciences raises $5 million to fund novel vitiligo therapy
The funding will enable the company in conducting Phase II human clinical trials for its potential drug candidate for ...
Biotech Startup Ahammune Biosciences Raises $5 Million in Series A Funding
Ahammune Biosciences, a clinical-stage therapeutics company focused on developing new treatments for skin diseases, has ...
entrackr13h
Biotech startup Ahammune Biosciences raises $5 Mn led by pi Ventures
Biotech startup Ahammune Biosciences has raised $5 million in Series A funding round led by pi Ventures. The round also ...
AbbVie: Upadacitinib Phase 3 Trials' Post-hoc Analysis Show Positive Results In Atopic Dermatitis
Drug maker AbbVie (ABBV) announced Wednesday positive results from a new post-hoc analysis of Phase 3 Studies, demonstrating efficacy ...
The Citizen15h
Albinism Society of South Africa fundraiser celebrates uniqueness
Celebrating the success of the Albinism Society of South Africa (ASSA) fundraising event held at Birchwood Hotel recently are ...
Rolling Out2h
The ultimate guide to at-home facials: Steps, tips and what to avoid
Follow these steps to create a luxurious at-home facial that rivals professional treatments: Start with a double cleansing ...
Ozempic can improve a common, chronic skin condition, new study claims
Hidradenitis suppurativa is a lesion-causing inflammatory disorder that affects at least 1 in 100 people and is strongly ...
Prevention20h
How to Do an At-Home Facial in 7 Steps, According to Skin Experts
From microdermabrasion treatments to hydrafacials to “vampire” facials there are a whole host of in-office skincare services designed to help you achieve healthy skin. These treatments, typically ...
New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
AbbVie (NYSE: ABBV) today announced positive results from a new post-hoc analysis from the Measure Up 1 and Measure Up 2 Phase 3 studies. The analysis evaluated the efficacy of upadacitinib (15 mg or ...